Ziad Hijazi: Refining Risk Assessment in Atrial Fibrillation Without Oral Anticoagulation
Ziad Hijazi, Senior Medical Director at Thermo Fisher Scientific, shared a post on LinkedIn about a recent article by Maria Tomasdottir et al, published in BMJ journals, adding:
“Refining risk assessment in atrial fibrillation without oral anticoagulation
Our new study shows that NT-proBNP provides important prognostic information in patients with AF not receiving anticoagulation, irrespective of presenting rhythm.
The findings strengthen the evidence underpinning biomarker-based risk stratification in this important but less-studied AF population, with relevance for clinical risk assessment and for patient characterization and enrichment strategies in clinical trials.
Proud to see this work by our PhD student Maria Tomasdottir at Uppsala University published in Heart.”
Title: NT-proBNP in relation to clinical characteristics and cardiovascular outcomes in non-anticoagulated patients with atrial fibrillation
Authors: Maria Tomasdottir, Jonas Oldgren, Johan Lindbäck, Alexander Benz, John W Eikelboom, Agneta Siegbahn, Lars Wallentin
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 7, 2026, 16:44Amor Salah: 2026 NCS/SCCM Guidelines for Managing Antithrombotic-Associated ICH
-
Oct 7, 2026, 16:04NETs in Thrombosis: From Mechanism to Therapeutic Target
-
Oct 7, 2026, 15:28Amir Samimi: Prognostic Value of Platelet Count in Resected HNSCC
-
Oct 7, 2026, 15:21Eloïse Laouenan: Bridging Immunity and Thrombosis in MVTE
-
Oct 7, 2026, 15:10Uthra Sundaram: Honouring Donors During International Plasma Awareness Week
-
Oct 7, 2026, 15:04Daniel Victor Ortigoza: Should Frail Older Patients With AF Switch From VKA to DOACs?
-
Oct 7, 2026, 14:53Susan Noone: Donor Turned Recipient Shares Lifesaving Transfusion Story
-
Oct 7, 2026, 14:49Aimee Burtenshaw: The Impact of the Infected Blood Inquiry on Hospital Transfusion Laboratories
-
Oct 7, 2026, 14:41Vikash Jaiswal: Does Timing Matter for Calcium in Pre-Eclampsia Prevention?